Short Summary
Charter Communications' IPR petition against Iarnach Technologies' DOCSIS auto‑configuration patent is challenged by the patent owner, who argues the petitioner's reply adds new, undisclosed arguments, violating the IPR rules. The patent owner seeks dismissal of the new arguments and confirmation of the patent's validity.
Detailed Summary
In IPR2024‑01287, Charter Communications seeks to invalidate claims of Iarnach Technologies' U.S. Patent No. 9,287,982 covering service auto‑configuration methods for DOCSIS provisioning. The patent owner’s sur‑reply contends that the petitioner's reply introduces new arguments and claim constructions—particularly regarding the “service auto‑configuration” and “back‑office management system” terms—that were not disclosed in the original petition, constituting an impermissible “unfair surprise.” Citing statutory requirements under 35 U.S.C. §§ 311 and 312 and numerous Federal Circuit precedents, the owner argues the Board must reject these late‑filed theories and uphold the patent’s validity.
Practitioner Note
This case demonstrates the evidentiary and procedural standards applied in patent matters before local courts. Understanding the court's reasoning in Charter Communications, Inc. vs Iarnach Technologies Limited is valuable context for structuring arguments or assessing risk in similar proceedings.
Related Cases
Jeisys Medical Inc. et al.vsSerendia, LLC
Jeisys Medical and Serendia settled their IPR dispute over U.S. Patent 9,775,774 and jointly moved to terminate the proceeding.
Medtronic, Inc.vsMoskowitz Family LLC
Medtronic has filed an IPR petition seeking to invalidate claims 8, 9, 13, and 17‑21 of U.S. Patent No. 12,011,367, which cover a zero‑profile expandable intervertebral spacer. The petition relies on the Palmatier patent as prior art to argue anticipation and obviousness.
Cisco Systems, Inc.vs--
Cisco Systems has filed a petition for inter partes review of U.S. Patent 8,780,887, asserting that its ten claims are obvious over the Pankratov prior‑art reference. The petition seeks institution of the IPR and cancellation of the challenged claims.
Merck Sharp & Dohme LLCvsHalozyme, Inc. et al.
Merck has filed a post‑grant review petition challenging Halozyme’s U.S. Patent 12,077,791 covering modified PH20 hyaluronidase proteins. The petition asserts that the claims are overly broad and lack both written description and enablement under 35 U.S.C. §112(a). Merck seeks institution of the proceeding and cancellation of all claims.
Alpinestars S.p.A et al.vsDainese S.p.A.
Alpinestars and Dainese have executed a settlement that ends all pending cross‑border patent disputes over airbag technology for motorcyclists. The agreement includes dismissal of lawsuits, withdrawal of oppositions, and a mutual non‑challenge pledge.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.
Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.